Key facts
- This page summarizes David Drutz's Form 4 filing for Altimmune, Inc. (ALT).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2024, 18:05.
David Drutz - 19 Aug 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)
- Reporting relationship
- Director
- Issuer ticker
- ALT
- Reported as of
- 19 Aug 2024
- Net transaction value
- -$4,172
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2024, 18:05:08 UTC
- Prior SEC filing
- 29 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Shutterly, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Drutz filed Form 4 for Altimmune, Inc. (ALT) on 20 Aug 2024.
Change
- Previous filing in this sequence was filed on 29 Sep 2023.
- Current net transaction value: -$4,172.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALT
transaction
Common Stock, par value $0.0001
Options Exercise
- Transaction value
- $52,000
- Shares
- +20,000
- Change %
- +67%
- Price
- $2.60
- Shares after
- 49,785
- Date
- 19 Aug 2024
- Ownership
- See Footnote
- Footnotes
- F1, F2
ALT
transaction
Common Stock, par value $0.0001
Sale
- Transaction value
- $54,241
- Shares
- -7,827
- Change %
- -16%
- Price
- $6.93
- Shares after
- 41,958
- Date
- 19 Aug 2024
- Ownership
- See Footnote
- Footnotes
- F2, F3
ALT
transaction
Common Stock, par value $0.0001
Options Exercise
- Transaction value
- $54,375
- Shares
- +21,750
- Change %
- +52%
- Price
- $2.50
- Shares after
- 63,708
- Date
- 19 Aug 2024
- Ownership
- See Footnote
- Footnotes
- F1, F2
ALT
transaction
Common Stock, par value $0.0001
Sale
- Transaction value
- $56,306
- Shares
- -8,184
- Change %
- -13%
- Price
- $6.88
- Shares after
- 55,524
- Date
- 19 Aug 2024
- Ownership
- See Footnote
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALT
transaction
Derivative
Stock Options (option to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 19 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001
- Underlying amount
- 20,000
- Exercise price
- $2.60
- Footnotes
- F4
ALT
transaction
Derivative
Stock Options (option to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -21,750
- Change %
- -83%
- Price
- $0.000000
- Shares after
- 4,350
- Date
- 19 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001
- Underlying amount
- 21,750
- Exercise price
- $2.50
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC.
Footnote F2
Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
Footnote F3
This sale represents shares sold to cover the exercise price.
Footnote F4
The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.
Footnote F5
The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date.
SEC remarks
Exhibit 24 - Power of Attorney